Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, the company's holding subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (...
Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Hefeng”), a holding subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2024B01791) issued by the State Drug Administration for metoclopramide hydrochloride injections. The drug passed the consistent evaluation of the quality and efficacy of generic drugs.
Metoclopramide hydrochloride injections are mainly used to relieve vomiting. These include chemotherapy, radiotherapy, surgery, brain injury, post-traumatic brain injury, sea-air work, and drug-induced vomiting; symptomatic treatment of nausea and vomiting symptoms of various diseases such as acute gastroenteritis, biliary pancreas, and uremia; use before diagnostic duodenal intubation to help smooth intubation; and gastrointestinal barium X-ray examinations, which can reduce nausea and vomiting reactions and promote the passage of barium agents. As of the announcement date, the company has invested about RMB 4.53 million in R&D expenses for the drug's consistency evaluation.